The cost-effectiveness of treatment in chronic HBV non-cirrhotic hepatitis – finite versus long-life therapy by unknown
POSTER PRESENTATION Open Access
The cost-effectiveness of treatment in chronic HBV
non-cirrhotic hepatitis – finite versus long-life
therapy
Cristina Popescu1,2*, Gabriel Adrian Popescu1,2, Alina Lobodan1, Mihaela Rădulescu1,2, Anca-Ruxandra Negru1,
Roxana Petre1, Violeta Molagic1, Cristina Covaliov1, Adriana Manea1, Victoria Aramă1,2
From The 10th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof Dr Matei Bals”
Bucharest, Romania. 15-17 October 2014
Background
Although the ideal end point of chronic HBV hepatitis
therapy is HBsAg loss, a realistic end point is the induc-
tion of sustained virological remission. The definitions
of virological responses vary according to therapeutic
regimen: viral load <2000 IU/mL after interferon (IFN)
regimens and undetectable HBV-DNA during nucleo-
side/nucleotide analogues (NNA) regimens. Objective:
To compare the direct costs of medication between two
therapeutic strategies: NNA versus NNA after IFN in
non-cirrhotic patients without contraindications for IFN.
Methods
We made a cost simulation analysis, in order to establish
the best therapeutic strategy in HBV hepatitis. The rate of
response after IFN therapy was about 40%. We theoreti-
cally compared the treatment costs for two groups of 100
patients: group 1 treated with entecavir 0.5 mg/day and
group 2, treated one year with IFN and then with entecavir
in non-responders to IFN. In Romania the cost of IFN is
220 Euro/dose and the cost of entecavir 0.5 mg is 410
Euro/month.
Results
IFN cost for one patient who received 48 weeks of therapy
is 10,560 Euro. For 100 patients the cost is 1,056,000 Euro.
The cost of entecavir for one patient, per year is 4920
Euro. For 100 patients the cost of therapy per year is
492,000 Euro. If the IFN response is 20%, for 100 analyzed
patients, 80 patients will be subsequently treated with
entecavir. If entecavir will be recommended for 5 years the
costs are: in group 1 – 2,460,000 Euro for 100 patients and
in group 2 – 2,574,960 Euro (1,000,560 Euro for IFN plus
1,574,400 Euro for 80 patients treated 4 years with enteca-
vir). The costs in these two groups are similar; the use of
IFN is not cost-effective. If entecavir will be recommended
for 10 years the costs are: in group 1- 4,920,000 Euro for
100 patients, in group 2 – 4,542,960 Euro (1,000,560 Euro
for IFN plus 3,542,400 Euro for 80 patients treated 9 years
with entecavir). A similar analysis for 40% response to
IFN, shown that the supplementary cost in group one is
278,640 Euro for 5 years and 1,262,640 Euro for 10 years.
Conclusion
We need real life studies in order to appreciate the rate
and the durability of immune response after IFN therapy.
If this rate is 20%, the use of IFN is cost-effective only if
entecavir will be used for 10 years or more. For 40%
response the use of IFN seems to be cost effective regard-
less the duration of entecavir therapy.
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